GLP-1 receptor agonists have transformed the weight loss landscape. Medications like Wegovy, Ozempic, Mounjaro, and Zepbound have helped millions of people achieve clinically significant weight loss — something that was extremely difficult with diet and exercise alone. This guide covers how these medications work, their effectiveness, costs, side effects, and who should consider them.
What Are GLP-1 Medications?
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications originally developed to treat type 2 diabetes. They mimic the action of a natural hormone called GLP-1, which is released in the gut after eating. This hormone signals the brain that you're full, slows down stomach emptying, and helps regulate blood sugar.
By harnessing this mechanism, GLP-1 medications help people eat significantly less without the constant battle against hunger that makes traditional dieting so difficult. Clinical trials have shown average weight loss of 15-22% of body weight — results that rival bariatric surgery.
How GLP-1 Medications Work
These medications work through three primary mechanisms:
- Appetite suppression: GLP-1 acts on the hypothalamus in the brain to reduce hunger signals and increase feelings of fullness
- Delayed gastric emptying: Food stays in your stomach longer, prolonging the sensation of fullness after meals
- Blood sugar regulation: They stimulate insulin release and suppress glucagon, improving glycemic control
GLP-1 Medications Comparison Table
| Medication | Active Ingredient | FDA Status | Avg Weight Loss | Monthly Cost |
|---|---|---|---|---|
| Wegovy | Semaglutide 2.4mg | Approved for weight loss | 15-17% | $1,349 (without insurance) |
| Ozempic | Semaglutide 0.5-2mg | Approved for diabetes (off-label for weight loss) | 10-14% | $935 (without insurance) |
| Mounjaro | Tirzepatide | Approved for diabetes (off-label for weight loss) | 17-22% | $1,059 (without insurance) |
| Zepbound | Tirzepatide | Approved for weight loss | 17-22% | $1,059 (without insurance) |
Wegovy (Semaglutide 2.4mg) — Best for Most Patients
Effectiveness: 4.7/5 — Wegovy is the only GLP-1 medication specifically FDA-approved for chronic weight management. In the STEP trials, participants lost an average of 15-17% of their body weight over 68 weeks.
Wegovy is a once-weekly injectable pen that delivers 2.4mg of semaglutide. It's taken on the same day each week, with or without food. The medication comes in pre-set pens, so there's no need for manual dosing. Treatment begins with a low dose (0.25mg weekly) that is gradually increased every four weeks to reduce side effects.
Best for: Adults with a BMI of 30 or higher, or those with a BMI of 27+ with at least one weight-related health condition such as hypertension, type 2 diabetes, or sleep apnea.
Ozempic (Semaglutide) — Diabetes-Focused Option
Ozempic contains the same active ingredient as Wegovy (semaglutide) but at lower doses and is FDA-approved specifically for type 2 diabetes management. Many doctors prescribe it off-label for weight loss when Wegovy is unavailable or too expensive. The maximum weekly dose for Ozempic is 2mg, compared to Wegovy's 2.4mg, which may result in slightly less weight loss.
Ozempic also reduces the risk of major cardiovascular events in people with type 2 diabetes and established heart disease — a significant benefit for that patient population.
Mounjaro & Zepbound (Tirzepatide) — Dual Action
Mounjaro (for diabetes) and Zepbound (for weight loss) contain tirzepatide, which works on two receptors instead of one — both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism appears to produce even greater weight loss than semaglutide alone.
In the SURPASS trials, tirzepatide produced an average weight loss of 17-22% of body weight at the highest dose (15mg weekly). The SURMOUNT trials for Zepbound showed similar results for weight loss specifically.
Both medications are once-weekly injections with a similar titration schedule to semaglutide products.
Common Side Effects
GLP-1 medications are generally well tolerated, but side effects are common, especially during the initial titration period:
- Nausea — the most common side effect, affecting up to 44% of users; usually improves over time
- Diarrhea — reported in about 30% of patients
- Vomiting — less common but can occur, especially with higher doses
- Constipation — affects roughly 24% of users
- Injection site reactions — mild redness or irritation at the injection site
- Fatigue — some users report reduced energy levels, particularly early on
Important: In rare cases, GLP-1 medications have been associated with pancreatitis (inflammation of the pancreas), gallbladder disease, and thyroid C-cell tumors in animal studies. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use these medications. Always discuss your full medical history with your healthcare provider before starting treatment.
Who Should Consider GLP-1 Medications?
Candidates for Treatment
- Adults with obesity (BMI ≥ 30)
- Adults with overweight (BMI ≥ 27) plus at least one weight-related health condition
- People who have not achieved adequate weight loss with lifestyle changes alone
- Those without contraindicating medical conditions
Who Should NOT Use These Medications
- Pregnant or breastfeeding women
- People with a history of pancreatitis
- Patients with personal or family history of medullary thyroid carcinoma (MTC)
- Those with Multiple Endocrine Neoplasia type 2 (MEN 2)
- People with severe gastrointestinal disease
Cost and Insurance Coverage
Without insurance, GLP-1 medications can cost $900-$1,350 per month. However, several factors can reduce out-of-pocket costs significantly:
- Insurance coverage: Many health insurance plans now cover Wegovy and Zepbound for weight loss, particularly if obesity-related comorbidities are documented
- Manufacturer savings programs: Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Zepbound/Mounjaro) offer savings cards that can reduce costs to as low as $25 per month for eligible patients
- Medicare coverage: Since 2023, Medicare Part D can cover obesity medications including Wegovy when prescribed for cardiovascular risk reduction
- PBMI coverage: Coverage varies widely — always verify with your specific plan before starting treatment
What to Expect: Timeline and Results
| Week | Expected Progress |
|---|---|
| Weeks 1-4 | Initial side effects (nausea, appetite reduction); minimal weight loss |
| Weeks 5-12 | Appetite suppression fully active; noticeable weight loss begins (2-5 lbs) |
| Weeks 13-24 | Continued steady weight loss; 5-10% body weight loss typical |
| Weeks 25-52 | Plateau may occur; dose optimization; continued loss to 10-15% |
| Week 68+ | Maximum clinical weight loss (15-22%); maintenance phase begins |
Lifestyle While on GLP-1 Treatment
GLP-1 medications are most effective when combined with dietary changes and increased physical activity. While the medication dramatically reduces appetite, making nutritious food choices ensures you get adequate protein, fiber, vitamins, and minerals on a lower calorie intake.
Key recommendations:
- Prioritize protein: Aim for 0.8-1g of protein per pound of target body weight daily to preserve lean muscle mass
- Stay hydrated: Drink at least 64oz of water daily, as dehydration is a risk with reduced food intake
- Eat slowly: GLP-1 medications slow gastric emptying; eating too quickly can cause discomfort
- Light exercise: Incorporate both cardio and resistance training; protein intake supports muscle preservation
- Track intake: Even with reduced appetite, monitoring food intake helps ensure nutritional adequacy
Discontinuation: What Happens When You Stop?
One critical thing to understand about GLP-1 medications is that they must be continued indefinitely to maintain weight loss. Studies show that when people stop taking these medications, they regain approximately two-thirds of the weight they lost within a year. This is not a failure of the medication — it's simply the nature of obesity as a chronic, relapsing condition.
Before starting, consider whether long-term medication use is acceptable and affordable for you. Some patients plan for eventual dose reduction or discontinuation while maintaining results through strict lifestyle adherence.
GLP-1 vs. Traditional Weight Loss Methods
✅ GLP-1 Advantages
- Clinically proven 15-22% weight loss
- Reduces hunger dramatically
- Improves metabolic health markers
- Once-weekly injection is convenient
- May reduce cardiovascular risk
- Addresses biological drivers of obesity
❌ GLP-1 Drawbacks
- Expensive without insurance coverage
- Requires ongoing use for maintenance
- GI side effects are common
- Injection-based (not oral)
- Not suitable for everyone
- Shortages have affected availability
Our Verdict — 4.5/5
GLP-1 medications represent a genuine breakthrough in obesity treatment. For people who have struggled with weight loss through diet and exercise alone, these medications can be transformative. The data is compelling: 15-22% body weight loss is simply not achievable for most people without pharmacotherapy or surgery.
The main barriers are cost, availability, and the requirement for long-term use. If your budget allows and your doctor confirms you're a good candidate, GLP-1 therapy can provide the metabolic reset that makes lasting weight management possible. Wegovy and Zepbound are our top recommendations based on FDA approval status and clinical trial results.